Fluoride ion and phosphines as nucleophilic catalysts: Synthesis of 1,4-benzothiazepines from cyclic sulfenamides

Journal of Organic Chemistry

Volumn 74, Issue 10, 2009, Pages 3936-3939

  Spitz, Cédric ^a   Lohier, Jean François ^a   Santos, Jana Sopkova De Oliveira ^b   Reboul, Vincent ^a   Metzner, Patrick ^a  

^a CNRS   (France)

^b CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOM ECONOMY; CHEMICAL EQUATIONS; ELECTRON-DEFICIENT; ENANTIOPURE; FLUORIDE ION; HIGH EFFICIENCY; SULFENAMIDE; SULFENAMIDES;

ACETYLENE; CATALYSIS; LIGHTING; PHOSPHORUS COMPOUNDS;

CATALYSTS;

ACETYLENE; BENZOTHIAZEPINE DERIVATIVE; FLUORIDE ION; PHOSPHINE DERIVATIVE; SULFENAMIDE DERIVATIVE;

ADDITION REACTION; ARTICLE; CATALYST; ELIMINATION REACTION; REACTION ANALYSIS; REACTION TIME; SYNTHESIS;

EID: 65949088576     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo900449a     Document Type: Article

References (60)

1. (a) Davis, F. A.; Nadir, U. K. Org. Prep. Proced. Int. 1979, 11, 35.
2. (b) Perrio, S.; Reboul, V.; Metzner, P. In Science of Synthesis: Compounds with two carbon-heteroatom bonds; Ramsden, C. A., Ed.; Thieme: Stuttgart, 2007; Vol.31a, p 1041.
3. (c) Taniguchi, N. Synlett 2007, 12, 1917.
4. Welch, W. M. J. Org. Chem. 1976, 41, 2220.
5. Buncel, E.; Um, I.-H. Tetrahedron 2004, 60, 7801.
6. (a) Heimer, N. E.; Field, L. J. Org. Chem. 1970, 35, 3012.
7. (b) Davis, F. A. Int. J. Sulfur Chem. 1973, 81, 71.
8. (c) Craine, L.; Raban, M. Chem. Rev. 1989, 89, 689.
9. Sobhani, S.; Fielenbach, D.; Marigo, M.; Wabnitz, T. C.; Joergensen, K. A. Chem.-Eur. J. 2005, 11, 5689.
10. Zhao, G.-L.; Rios, R.; Vesely, J.; Ericksson, L.; Córdova, A. Angew. Chem., Int. Ed. 2008, 47, 8468.
11. Matsuo, J.-i.; Iida, D.; Yamanaka, H.; Mukaiyama, T. Tetrahedron 2003, 59, 6739.
12. (a) Kuniyasu, H.; Hiraike, H.; Morita, M.; Tanaka, A.; Sugoh, K.; Kurosawa, H. J. Org. Chem. 1999, 64, 7305.
13. (b) Knapton, D. J.; Meyer, T. Y. J. Org. Chem. 2005, 70, 785.
14. (c) Knapton, D. J.; Meyer, T. Y. Org. Lett. 2004, 6, 687.
15. (d) Rescourio, G.; Alper, H. J. Org. Chem. 2008, 73, 1612.
16. Savarin, C.; Srogl, J.; Liebeskind, L. S. Org. Lett. 2002, 4, 4309.
17. Shin, J. M.; Cho, Y. M.; Sachs, G. J. Am. Chem. Soc. 2004, 126, 7800.
18. Hemenway, J. N.; Nti-Addae, K.; Guarino, V. R.; Stella, V. J. Bioorg. Med. Chem. Lett. 2007, 17, 6629.
19. (a) Sivaramakrishnan, S.; Keerthi, K.; Gates, K. S. J. Am. Chem. Soc. 2005, 127, 10830.
20. (b) Sarma, B. K.; Mugesh, G. J. Am. Chem. Soc. 2007, 129, 8872.
21. Le Fur, N.; Mojovic, L.; Plé, N.; Turck, A.; Reboul, V.; Metzner, P. J. Org. Chem. 2006, 71, 2609.
22. Synthesis of 1,4-benzothiazepine core: (a) Fodor, L.; Szabo, J.; Bernath, G.; Parkanyi, L; Sohar, P. Tetrahedron Lett. 1981, 22, 5077.
23. (b) Kraus, G. A.; Yue, S. J. Org. Chem. 1983, 48, 2936.
24. (c) Brewer, M. D.; Burgess, M. N.; Dorgan, R. J. J.; Elliott, R. L.; Mamalis, P.; Manger, B. R.; Webster, R. A. B. J. Med. Chem. 1989, 32, 2058.
25. (d) Nefzi, A.; Ong, N. A.; Giulianotti, M. A.; Ostreh, J. M.; Houghten, R. A. Tetrahedron Lett. 1999, 40, 4939.
26. (e) Katritzky, A. R.; Xu, Y.-J.; He, H.-Y.; Mehta, S. J. Org. Chem. 2001, 66, 5590.
27. (f) Neo, A. G.; marcos, C. F.; Marcaccini, S.; Pepino, R. Tetrahedron Lett. 2005, 46, 7977.
28. Atherosclerosis: Brieaddy, L. E. WO Patent 016055, 1993.
29. Hyperlipidaemia: (a) Brieaddy, L. E. WO Patent 005188, 1996.
30. (b) Sasahara, T.; Mohri, M. WO Patent 020421, 2004.
31. (c) Starke, I.; Alenfalk, S.; Nordberg, M. P.; Dahlstrom, M. U. J.; Bostrom, S. J. Lemurell, M. A.; Wallberg, A. C. WO Patent 076430, 2004.
32. (d) Sasahara, T.; Mohri, M.; Kasahara, K. I. WO Patent 082874, 2005.
33. (e) Frick, W.; Glombik, H.; Heuer, H.; Schaefer, H.-L.; Theis, S. WO Patent 009655, 2007.
34. Muscle relaxation accelerator: (f) Kaneko, N. WO Patent 105793, 2005.
35. Cell death of cardiac muscles: (g) Kaneko, N.; Oosawa, T.; Sakai, T.; Oota, H. WO Patent 012148, 1992.
36. Diabete: (h) Nagase, T.; Sato, Y.; Eiki, J. WO Patent 053548, 2002.
37. Cardiac hypertrophy: IMarks, A. R.; Lehnart, S. E. WO Patent 021439, 2008.
38. Anti-arrythmic and heart failure: (j) Marks, A. R.; Landry, D. W.; Deng, S.; Cheng, Z. Z. WO Patent 101496, 2006.
39. Kondo, T.; Baba, A.; Nishi, Y.; Mitsudo, T. Tetrahedron Lett. 2004, 45, 1469.
40. For excellent reviews: (a) Lu, X.; Zhang, C.; Xu, Z. Acc. Chem. Res. 2001, 34, 535.
41. (b) Methot, J. L.; Roush, W. R. Adv. Synth. Catal. 2004, 346, 1035.
42. (c) Nair, V.; Menon, R. S.; Sreekanth, A. R.; Abhilash, N.; Biju, A. T. Acc. Chem. Res. 2006, 520.
43. (d) Ye, L.-W.; Zhou, J.; Tang, Y. Chem. Soc. Rev. 2008, 1140.
44. Sriramurthy, V.; Barcan, G. A.; Kwon, O. J. Am. Chem. Soc. 2007, 129, 12928.
45. The molecular structure of 3a was confirmed by X-ray crystallographic analysis (see Supporting Information). Interestingly, two conformations were positioned in the unit cell: either the iso-propyl group is in a pseudoequatorial or is in a pseudoaxial disposition, as in the molecular structures of sulfenamides 1a and 1c.
46. 2 at 40 °C, less than 10% of conversion was observed.
47. Henke, A.; Srogl, J. J. Org. Chem. 2008, 73, 7783.
48. Gorgues, A.; Stéphan, D.; Cousseau, J. J. Chem. Soc., Chem. Commun. 1989, 1493.
49. Hudlicky, M. J. Fluorine. Chem. 1988, 40, 99.
50. 3a was obtained in 99% ee (Chiral HPLC, Daicel AD).
51. The ring expansion on the benzylic position was not observed: Voskressensky, L. G.; Akbulatov, S. V.; Borisova, T. N.; Varlamov, A. V. Tetrahedron 2006, 62, 12392.
52. This compound was prepared from DMAD in two steps: Hopf, H.; Witulski, B. In Modern Acetylene Chemistry; Stang, P. J., Diederich, F., Ed.; VCH: Weinheim, 1995; p 60.
53. This compound was prepared from dichloroacetylene in two steps: (a) Riera, A.; Cabré, F.; Moyano, A.; Pericàs, M. A.; Santamaría, J. Tetrahedron Lett. 1990, 31, 2169.
54. (b) Riera, A.; Martí, M.; Moyano, A.; Pericàs, M. A.; Santamaría, J. Tetrahedron Lett. 1990, 31, 2173.
55. Bis(arylsulfonyl)acetylenes were not used due to their instability at room temperature: (c) Pasquato, L.; De Lucchi, O.; Krotz, L. Tetrahedron Lett. 1991, 32, 2177.
56. 19F NMR but, due to problems of solubility, no characteristics signal has been found.
57. The corresponding thiosulfinate was not observed.
58. Fifty-five percent of starting material 1a was recovered.
59. However, the fluoride ion has been reported as catalyst, in a desilylation-defluorination sequence: Uneyama, K. J. Fluorine. Chem. 2007, 128, 1087.
60. 3CN (rt to 80 °C).